Scientific Advisory Board

The Brigham Research Institute’s Scientific Advisory Board is tasked with providing strategic counsel and vision to further enhance research at Brigham and Women’s Hospital.  Chaired by BWH trustee Jeff Leiden, MD, PhD, the board is comprised of scientists, venture capitalists and pharmaceutical leaders.

Sangeeta N. Bhatia, MD, PhD

Sangeeta N. Bhatia is a cancer researcher, Massachusetts Institute of Technology professor and biotech entrepreneur who adapts technologies developed in the computer industry for medical innovation. Among her team’s inventions are microlivers that model diseases of the liver, synthetic biomarkers for noninvasive disease monitoring, and living medical devices to support patients with organ failure.

Dr. Bhatia holds an M.D. from Harvard Medical School, a Ph.D. from MIT, and a Bachelor’s degree from Brown University. At MIT, she is the John J. and Dorothy Wilson Professor at the Institute for Medical Engineering and Science and Electrical Engineering and Computer Science, inaugural director of the Marble Center for Cancer Nanomedicine and a member of the Ludwig Center for Molecular Oncology – both part of the Koch Institute for Integrative Cancer Research at MIT. Bhatia is also a Howard Hughes Medical Institute investigator, on the Board of Directors at Vertex Pharmaceuticals, and an elected member of the National Academy of Science, the National Academy of Medicine, the National Academy of Engineering, and Brown University’s Board of Trustees.

Dr. Bhatia has been honored with the Lemelson-MIT Prize for her research contributions, and the Heinz Medal for groundbreaking inventions and advocacy for women in STEM fields. She has presented her vision for the application of engineering solutions to solve medical problems on international stages such as the World Economic Forum, TED, the Gates Grand Challenges, and the Biden Cancer Moonshot.

James Bradner, MD

James (Jay) Bradner, MD is President of the Novartis Institutes for BioMedical Research (NIBR). Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. He was also associate director of the Center for the Science of Therapeutics at the Broad Institute of MIT and Harvard. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 150 scientific publications and 30 US patent applications.

Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women’s Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

Gerald Chan, PhD

Gerald Chan co-founded Morningside in 1986 as a private investment group with venture capital, private equity and property investments.

In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such as oncolytic viruses (BioVex, DNAtrix), immuno-oncology (Aduro), modified cytotoxic agents (Nucana), modified tumor microenvironment (Vigeo) and novel targets for therapeutic intervention (CellCentric). Investments in the infectious disease area include novel antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Other investments cover the therapeutic areas of autoimmune diseases (Kezar), CNS disorders (Orthogonal, Pinteon, Cognito, Cognoa), and rare orphan diseases (Stealth, Apellis).

Gerald is a member of Harvard University’s Global Advisory Council, the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He sits on the board of the Scripps Research Institute. He chairs the Overseers Committee of the Morningside College of Chinese University of Hong Kong and the Innovation Advisory Committee of the Wellcome Trust in UK.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute. Chinese University of Hong Kong, University of Glasgow, Hong Kong University of Science and Technology, Scripps Research Institute and University of Massachusetts Boston have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University in 2012 and membership in the American Academy of Arts and Sciences in 2017.

Susan Hockfield, PhD

Susan Hockfield is Professor of Neuroscience and President Emerita at the Massachusetts Institute of Technology; she served as the sixteenth president from 2004 to 2012, was the first woman and the first life scientist to lead the Institute. Prior to MIT, she was the William Edward Gilbert Professor of Neurobiology, Dean of the Graduate School of Arts and Sciences (1998-2002), and Provost (2003-2004) at Yale University.

After earning a BA in biology from the University of Rochester and a PhD from Georgetown University at the School of Medicine, Dr. Hockfield was an NIH postdoctoral fellow at the University of California at San Francisco. She then joined the scientific staff at the Cold Spring Harbor Laboratory in New York. In 1985, Dr. Hockfield became a faculty member at Yale University, where she focused her research on brain development and glioma, a deadly form of brain cancer, and also pioneered the use of monoclonal antibody technology in brain research.

Dr. Hockfield serves as president of the American Association for the Advancement of Science, a director of General Electric, Partners Healthcare System, and the Council on Foreign Relations, a life member of the MIT Corporation, a trustee of the Boston Symphony Orchestra, and a board member of the Belfer Center at the Harvard Kennedy School. She has served as co-chair of President Obama’s steering committee of the Advanced Manufacturing Partnership, a working coalition of academic, government and industry leaders, a member of a Congressional Commission evaluating the Department of Energy laboratories and as Science Envoy with the U.S. Department of State. Dr. Hockfield is the recipient of the Charles Judson Herrick Award from the American Association of Anatomists, the Wilbur Lucius Cross Award from Yale University, the Meliora Citation from the University of Rochester, the Golden Plate Award from the Academy of Achievement, the Amelia Earhart Award from the Women’s Union, the Edison Achievement Award, and the Pinnacle Award for Lifetime Achievement from the Greater Boston Chamber of Commerce. She has received honorary degrees from national and international universities, and is an elected fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.

Jeffrey Leiden, MD, PhD (Chair)

Dr. Leiden is a physician/scientist who for the last 30 years, has dedicated his career to improving the lives of people with serious diseases. His experience spans all aspects of the academic, biotech, and pharmaceutical sectors. He is a cardiologist and molecular biologist who received his BA, MD and PhD degrees from the University of Chicago.

Between 1987 and 2000, he pursued a career in academia first as Professor of Medicine and Chief of Cardiology at the University of Chicago and then as Professor of Medicine at the Harvard Medical School. Following his work in academia, he served as President, Chief Operating Officer and Chief Scientific Officer of Abbott Laboratories. While at Abbott he led the development and commercialization of multiple breakthrough medicines including Humira for rheumatoid arthritis and other autoimmune diseases and Kaletra for HIV infection. From 2006 to 2011, Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm dedicated to developing new treatments by founding innovative biotech companies.

Since 2012 he has served as the Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals where he remains committed to helping people – from patients to employees and the local community. Under his leadership, Vertex has developed and delivered Kalydeco and Orkambi, the first and only precision medicines to treat the underlying cause of cystic fibrosis. During the next 3-5 years the company is well positioned to bring more transformative medicines to people with CF and other serious diseases. During his tenure as CEO, Dr. Leiden has also established a signature program to enhance STEM education among Boston high school students including building a dedicated science learning lab at Vertex headquarters and making a 3-year, $1.5 million commitment to the Boston Public Schools.

Dr Leiden holds a number of industry and hospital board positions, including the Scientific Advisory Board of Boston Children’s Hospital. He is a director of Quest Diagnostics and the Massachusetts Mutual Insurance Company. A supporter of the arts and a longtime advocate for encouraging a love of science at a young age, he also serves on the boards of the Boston Museum of Fine Art, the Boston Private Industry Council and the Governor’s STEM Advisory Council, and MA Digital Health Council, both of which he co-chairs.

He is an elected member of the National Academy of Medicine and the American Academy of Arts and Sciences.

Terry McGuire, MBA, MS

As a Founding Partner of Polaris Partners, Terry McGuire brings more than 30 years of successful early stage investing experience in medical and information technology companies.

Terry has invested in more than 50 companies. He co-founded Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkermes) and MicroCHIPS (private). Companies Terry has supported have touched more than 60 million patients and saved over 400,000 lives. These companies have raised over $6 billion in equity and corporate capital. As a group, they have achieved a combined peak enterprise value of over $50 billion.

In 2015, Terry was listed as one of Scientific American’s Worldview 100, visionaries who continue to reshape biotechnology and the world. In 2014, Terry was listed in Forbes’ Midas 100 List of Top Tech Investors, and also was chosen to receive the Irish America Healthcare & Life Sciences 50 Award. In 2013, Terry was listed as one of Forbes’ Top Life Sciences Investors. In 2011, Terry was listed in Forbes’ Midas 100 List of Top Tech Investors. He is also a recipient of the Massachusetts Society for Medical Research Award, and the Albert Einstein Award for Outstanding Achievement in the Life Sciences, awarded by Harvard and the City of Jerusalem. He was awarded honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science.

Terry is emeritus Chairman of the National Venture Capital Association.

Terry is chairman of the Thayer School of Engineering, Dartmouth College. He also sits on the boards of MIT’s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at Harvard Business School, and The Healthcare Initiative Advisory Board (HBS).

Terry holds an MBA from Harvard Business School, an MS in engineering from The Thayer School at Dartmouth College, and a BS in physics and economics from Hobart College.

Aviv Regev, PhD

Aviv Regev PhD, a computational and systems biologist, is a core member and Chair of the faculty at the Broad Institute, a professor of biology at MIT, and an Investigator at the Howard Hughes Medical Institute. Regev’s research centers on combining experimental and computational approach to decipher how complex molecular circuits function in cells and between cells in tissues. She is the founding director of the Klarman Cell Observatory and Cell Circuits Program at the Broad, and the Founding Co-Chair of the international initiative to build a Human Cell Atlas (HCA), whose mission is to create comprehensive reference maps of all human cells – the fundamental units of life – as a basis for both understanding human health and diagnosing, monitoring, and treating disease. Her lab has been a pioneer of single-cell genomics – inventing key experimental methods and computational algorithms in the field, and demonstrating how to apply it to understand cell taxonomies, histological organization, differentiation and physiological processes, and how to infer the molecular and cellular circuits that control the function of cells and tissues in health and disease. Among her honors are the NIH Director’s Pioneer Award, the Overton Prize and the Innovator Award from the International Society for Computational Biology (ISCB), the Earl and Thressa Stadtman Scholar Award from the American Society of Biochemistry and Molecular Biology, and the Paul Marks Prize. She is a Fellow of the International Society of Computational Biology and a Member of the National Academy of Sciences.

Michael Rosenblatt, MD

Dr. Rosenblatt’s career has been in academia, the pharmaceutical industry and biotech/venture. He is a physician, scientist, educator and leader in healthcare. He currently serves as Chief Medical Officer of Flagship Pioneering in Cambridge, MA. He was Executive Vice President and Chief Medical Officer for Merck from 2009-2016. Previously he was Dean, Tufts University School of Medicine. Prior to that, he was Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine at Harvard Medical School. He was President of Beth Israel Deaconess Medical Center (BIDMC) from 1999-2001, and earlier Director of the Harvard-MIT Division of Health Sciences and Technology and Senior VP for Research at Merck where he co-led worldwide development of alendronate (FOSAMAX) for osteoporosis. Before joining Merck the first time, he was Chief of the Endocrine Unit at the Massachusetts General Hospital.

Dr. Rosenblatt has been active in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius Pharmaceuticals, a company that has developed abaloparatide (TYMLOS) for osteoporosis. He is also currently on the Harvard Medical School Board of Fellows, and research advisory committees of the Massachusetts General Hospital, and Children’s Hospital (Boston).

Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his MD magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.

Geoffrey W. Smith, JD

Geoffrey W. Smith is the founder and Managing Partner of Digitalis Ventures, a venture capital firm that invests in fundamental new ideas in math and science to address complex health problems. He currently represents Digitalis as a Director of CareDox and GRO Biosciences, and as a Board Observer of Second Genome.

He is also a co-founder and General Partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments. Geoff currently represents Ascent on the Board of Directors of Azevan Pharmaceuticals, BackBeat Medical, BlinkBio, and Caliber Therapeutics, and is a Board Observer of Vivasure Medical. Previously, he was the founding Director of the Mount Sinai Institute of Technology and a Professor in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Geoff received a BA (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.

Elias Zerhouni, MD

Dr. Zerhouni was most recently the President, Global Research & Development, and a member of the Executive Committee for Sanofi from January 2011 to July 2018. Dr. Zerhouni’s academic career was spent at the Johns Hopkins University and Hospital where he was professor of Radiology and Biomedical engineering and senior adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health from 2002 to 2008. In that position he oversaw the NIH’s 27 Institutes and Centers with more than 18,000 employees and a budget of $29.5 billion (2008).

In November 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys. Dr. Zerhouni also served as senior fellow to the Bill and Melinda Gates foundation from 2009 to 2010 and senior advisor to the CEO of Sanofi. Dr. Zerhouni has founded or co-founded five start-up companies, authored more than 200 publications and holds several patents. He has assumed positions on several Boards, including most recently, the board of the Lasker Foundation, Research!America and the NIH Foundation. He is also a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering. He received the prestigious Legion of Honor medal from the French National Order in 2008, and was elected in 2010 as a member of the French Academy of Medicine and appointed as Chair of Innovation at the College de France in 2011.

Scientific Advisory Board Alumni

Carole Greider, PhD

Carol Greider, PhD is the Daniel Nathans Professor and Director of Molecular Biology and Genetics at Johns Hopkins University. Dr Greider is a molecular biologist who discovered the enzyme telomerase in 1984, working together with Elizabeth Blackburn at the University of California, Berkeley. Dr Greider pioneered research on the structure and function of telomeres, the ends of the chromosomes. She was awarded the 2009 Nobel Prize for Physiology or Medicine, along with Blackburn and Jack W. Szostak, for their discovery that telomeres are protected from progressive shortening by the enzyme telomerase.

Sue Siegel, MS

Sue Siegel is CEO of GE Ventures, GE’s growth and innovation business comprised of new market development, equity investing, new business creation and licensing. Sue has more than 30 years of experience in corporate and venture capital. Previously, as a financial VC, Sue led investments in personalized medicine, digital health, and life sciences at Silicon Valley-based Mohr Davidow Ventures.


Before venture capital, she was President and Board Member of Affymetrix (NASDAQ: AFFX), where she drove the company’s transformation from a pre-revenue start up to a global, multi-billion dollar market cap genomics leader. Prior to that, Sue drove strategy, technology development, licensing, manufacturing, as well as new market creation at Bio-Rad, DuPont, and Amersham. Sue has served on many private and public corporate boards. She currently serves on the Boards of: Stanford Hospital Board’s IT Committee, Harvard Partners’ Innovation Advisory Board, the Cleveland Clinic’s Innovation Council, University of California’s Innovation Council, and serves on the Executive Committee of Santa Clara University’s Center for Science, Technology, and Society’s Advisory Board.


She is a member of YPO-WPO, Women Corporate Directors, and a Henry Crown Fellow of the Aspen Institute. In the bestselling business book: Multipliers: How The Best Leaders Make Everyone Smarter, Sue was a featured “Multiplier.” She was recognized as one of “The 100 Most Influential Women in Silicon Valley” and Fortune’s “34 Leaders Who Are Changing Health Care.”